NCT00697632

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Mirati Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.

Detailed description

MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients. In this study, MGCD265 is orally administered on a daily basis to patients with advanced malignancies.

Conditions

• Advanced Cancer

Interventions

Type	Name	Description
DRUG	MGCD265	Oral daily administration without interruption

Timeline

• Start date: 2008-06-01
• Primary completion: 2018-09-01
• Completion: 2019-01-01
• First posted: 2008-06-16
• Last updated: 2019-02-12

Locations

19 sites across 3 countries: United States, Canada, South Korea